Gwangju, South Korea

A-Young Pyo

This inventor holds 1 USPTO granted patent. Top assignee: Chonnam National University. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: A-Young Pyo. Retrieved from https://idiyas.com/inventor/a-young-pyo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: A-Young Pyo: Innovator in Melanoma Treatment

Introduction

A-Young Pyo is a notable inventor based in Gwangju, South Korea. She has made significant contributions to the field of medical technology, particularly in the treatment of melanoma. Her innovative work focuses on developing a radioactive compound that enhances targeting ability for melanoma treatment.

Latest Patents

A-Young Pyo holds a patent for a radioactive compound designed for the treatment of melanoma. This invention relates to a radioactive compound with improved targeting ability compared to conventional contrast agents used for melanoma. The compound demonstrates a remarkable therapeutic effect on melanoma, showcasing its potential in medical applications.

Career Highlights

A-Young Pyo is affiliated with Chonnam National University, where she continues her research and development efforts. Her work has garnered attention for its innovative approach to treating melanoma, contributing to advancements in the medical field.

Collaborations

A-Young Pyo collaborates with esteemed colleagues, including Jung-Joon Min and Dong-Yeon Kim. Their combined expertise enhances the research and development of effective treatments for melanoma.

Conclusion

A-Young Pyo's contributions to melanoma treatment through her innovative radioactive compound highlight her role as a leading inventor in the medical field. Her work not only advances scientific knowledge but also offers hope for improved therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…